Drugs / human SARS-CoV 2 specific T lymphocytes
human SARS-CoV 2 specific T lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04762186 | Dec 2021 → Aug 2022 | — | University Hospital Cologne | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human SARS-CoV 2 specific T lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04762186 ↗ |
| Modality | Cell therapy | “viable human SARS-CoV-2-specific T cells” NCT04762186 ↗ |
| Route | Other | “single infusion over 15 to 30 minutes” NCT04762186 ↗ |